MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Consensus Rating of “Hold” by Brokerages

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) have been assigned an average rating of “Hold” from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $35.00.

A number of research firms have recently weighed in on INKT. Wall Street Zen upgraded shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings downgraded shares of MiNK Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. Finally, HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of MiNK Therapeutics in a report on Monday, May 18th.

Institutional Trading of MiNK Therapeutics

A hedge fund recently bought a new stake in MiNK Therapeutics stock. DRW Securities LLC purchased a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned approximately 0.55% of MiNK Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 2.87% of the stock is owned by institutional investors and hedge funds.

MiNK Therapeutics Price Performance

NASDAQ:INKT opened at $12.14 on Friday. The firm has a market capitalization of $60.46 million, a P/E ratio of -4.27 and a beta of 0.47. MiNK Therapeutics has a 1-year low of $6.80 and a 1-year high of $76.00. The company’s fifty day moving average price is $11.64 and its 200-day moving average price is $11.44.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.20. Equities analysts anticipate that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.